Updates: Retina
ARVO Highlights
About the conference: ARVO The ARVO conference took place in the New Orleans Ernest N. Morial Convention Center. With over 10 000 attendees, the venue was absolutely huge. If you…
Read update
Latest innovation in retina models brings a fully characterised Retina Pigment Epithelium (RPE)
Why develop an RPE model? Retinal pigment epithelium (RPE) cells play a vital role in the retina by forming the outer blood-retinal barrier and maintaining photoreceptor and visual…
Read update
Antibody drug conjugates (ADCs) – the role of in vitro models in safety assessment
One the fastest growing approaches to treat cancer is the use of antibody drug conjugates (ADCs). Since the approval of the first antibody drug conjugate in 2000,…
Read update
Gene therapy vectors: Preclinical testing with retinal organoids
Adeno Associated Virus (AAV) vectors have emerged as the most successful retinal gene therapy vectors following the FDA approval of Luxturna in 2017. This new gene therapy product is…
Read update
Retinal Organoids for Drug Discovery
Retinal diseases have been at the forefront of gene and cell therapy over the last 30 years with conditions such as macular degeneration and Stargardt disease likely to be…
Read update
iPSC-derived Retinal Organoids: an alternative in vitro model for drug discovery
What retinal models are available for drug development? Animal models are the most frequently used for investigating safety and efficacy of ophthalmic drugs. However, due to several key physiological differences,…
Read update
